- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06115408
Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma
October 29, 2023 updated by: Esraa Mosaad Awd El-sayed, Ain Shams University
This 2 arm randomized clinical trial will assess the impact of Dienogest and N-Acetyl Cysteine on volume reduction of uterine leiomyoma
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Group A women will receive Dienogest orally 2mg pills daily for 3 months .20 cases Group B women will receive NAC orally at a dose of 600 mg/day for 3 months ,20 cases
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Esraa Awd
- Phone Number: +201019000586
- Email: Awade0343@gmail.com
Study Locations
-
-
-
Cairo, Egypt
- Recruiting
- Ainshams university
-
Contact:
- Fatma Ebeid
- Email: dr.fatma_ebeid@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age: 20-45 years.
- Women with uterine leiomyoma (sub-mucous, sub-serous or intramural) based on transvaginal sonography criteria. Uterine fibroids most often appear as concentric, solid, hypoechoic masses. This appearance results from the prevailing muscle, which is observed at histologic examination. These solid masses absorb sound waves and therefore cause a variable amount of acoustic shadowing.
- Regular menstruation: regular period interval from 21 to 35 days.
Exclusion Criteria:
- Pregnant or menopausal women.
- History of malignancies, metabolic, hematologic, cardiac, thromboembolism, diabetes, renal or hepatic diseases.
- History of hormonal drug use or treatment for leiomyoma in the past 3 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drug;Dienogest
2mg pills oral daily
|
Clinical trial
Other Names:
|
Experimental: Drug;N-Acetylcysteine
600 mg/day oral daily
|
Clinical trial
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Leiomyoma volume change
Time Frame: 3 Monthes
|
Measure leiomyoma volume change in 3 dimensions in cm
|
3 Monthes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dysmenorrhea
Time Frame: 3 Monthes
|
according to the visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain.
The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain)
|
3 Monthes
|
Heavy menstrual bleeding
Time Frame: 3months
|
assess any abnormal uterine bleeding (AUB) by FIGO System is according to frequency, duration, regularity and flow volume.
|
3months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Amr Mahmoud, ain shams University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2023
Primary Completion (Estimated)
October 31, 2023
Study Completion (Estimated)
December 31, 2023
Study Registration Dates
First Submitted
March 9, 2023
First Submitted That Met QC Criteria
October 29, 2023
First Posted (Estimated)
November 3, 2023
Study Record Updates
Last Update Posted (Estimated)
November 3, 2023
Last Update Submitted That Met QC Criteria
October 29, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Connective Tissue Diseases
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Leiomyoma
- Myofibroma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protective Agents
- Respiratory System Agents
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Antioxidants
- Antidotes
- Contraceptives, Oral, Hormonal
- Free Radical Scavengers
- Expectorants
- Contraceptive Agents, Male
- Acetylcysteine
- N-monoacetylcystine
- Dienogest
Other Study ID Numbers
- Leiomyoma volume reduction
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All of individual participant data collecting during the trial ,after deidentification
IPD Sharing Time Frame
Immediately following publication.no
end date
IPD Sharing Access Criteria
Any purpose
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Leiomyoma
-
University of Sao PauloTerminated
-
Imam Abdulrahman Bin Faisal UniversityUnknownUterine Artery Embolization for Uterine LeiomyomataSaudi Arabia
-
University of California, San FranciscoUniversity of California, San Diego; University of California, Los Angeles; University... and other collaboratorsCompleted
-
General Hospital of Ningxia Medical UniversityCompletedUterine Leiomyomas
-
University of California, San FranciscoActive, not recruitingUterine FibroidsUnited States
-
InSightecCompletedUterine Fibroids | Uterine LeiomyomaUnited States, Canada
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedUterine Leiomyomata (Fibroids)United States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedUterine Leiomyomata (Fibroids)Japan
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedUterine Leiomyomata (Fibroids)Japan
-
Medical University of GrazAustrian Urogynecology Working Group (AUWG)CompletedUterine Fibroids | Uterine Leiomyoma | Abnormal Uterine Bleeding, UnspecifiedAustria
Clinical Trials on Dienogest 2 MG
-
Laboratorios Andromaco S.A.Completed
-
Ospedale Policlinico San MartinoCompletedEndometriosis | IVF | Endometriosis OvaryItaly
-
Laboratorios Andromaco S.A.Completed
-
Azienda Ospedaliero-Universitaria di ModenaUniversity of Modena and Reggio Emilia; Ministero della Salute, ItalyRecruiting
-
University of Erlangen-Nürnberg Medical SchoolTerminated
-
Laboratorios Andromaco S.A.Completed
-
American University of Beirut Medical CenterRecruitingEndometriosisLebanon
-
CicloMed LLCCmed Clinical ServicesCompletedAdvanced Solid TumorsUnited States
-
Galderma R&DCompletedHealthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected SkinFrance